EE05276B1 - Kasvaja nekroosifaktori sugulasligand - Google Patents

Kasvaja nekroosifaktori sugulasligand

Info

Publication number
EE05276B1
EE05276B1 EEP199900043A EE9900043A EE05276B1 EE 05276 B1 EE05276 B1 EE 05276B1 EE P199900043 A EEP199900043 A EE P199900043A EE 9900043 A EE9900043 A EE 9900043A EE 05276 B1 EE05276 B1 EE 05276B1
Authority
EE
Estonia
Prior art keywords
necrosis factor
tumor necrosis
cognate ligand
trell
ligand
Prior art date
Application number
EEP199900043A
Other languages
English (en)
Estonian (et)
Other versions
EE9900043A (et
Inventor
Chicheportiche Yves
L. Browning Jeffrey
Original Assignee
Biogen, Incorporated
The Faculty Of Medicine Of The University Of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, The Faculty Of Medicine Of The University Of Geneva filed Critical Biogen, Incorporated
Publication of EE9900043A publication Critical patent/EE9900043A/xx
Publication of EE05276B1 publication Critical patent/EE05276B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
EEP199900043A 1996-08-07 1997-08-07 Kasvaja nekroosifaktori sugulasligand EE05276B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2354196P 1996-08-07 1996-08-07
US2851596P 1996-10-18 1996-10-18
US4082097P 1997-03-18 1997-03-18
PCT/US1997/013945 WO1998005783A1 (en) 1996-08-07 1997-08-07 A tumor necrosis factor related ligand

Publications (2)

Publication Number Publication Date
EE9900043A EE9900043A (et) 1999-08-16
EE05276B1 true EE05276B1 (et) 2010-02-15

Family

ID=27362110

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900043A EE05276B1 (et) 1996-08-07 1997-08-07 Kasvaja nekroosifaktori sugulasligand

Country Status (26)

Country Link
EP (2) EP1591530B8 (da)
JP (3) JP4161084B2 (da)
KR (1) KR100543730B1 (da)
CN (2) CN1308451C (da)
AT (1) ATE307204T1 (da)
AU (1) AU736289B2 (da)
BG (1) BG64779B1 (da)
BR (1) BR9711046A (da)
CA (1) CA2262756C (da)
CZ (1) CZ297387B6 (da)
DE (1) DE69734397T2 (da)
DK (1) DK0956351T3 (da)
EA (1) EA003187B1 (da)
EE (1) EE05276B1 (da)
ES (1) ES2251737T3 (da)
HK (1) HK1025994A1 (da)
HU (1) HU226787B1 (da)
IL (1) IL128407A (da)
IS (1) IS2606B (da)
NO (2) NO326967B1 (da)
NZ (1) NZ334107A (da)
PL (1) PL188102B1 (da)
SI (1) SI0956351T1 (da)
SK (1) SK288012B6 (da)
TR (1) TR199900903T2 (da)
WO (1) WO1998005783A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2305713A1 (en) * 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
DE19829550C1 (de) * 1998-07-02 2000-01-27 Bosch Gmbh Robert Vorrichtung zum Verbinden von Bauteilen
BR0007556A (pt) * 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
AU784504B2 (en) * 1999-11-19 2006-04-13 Thomas V. Tittle TR3-specific binding agents and methods for their use
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
WO2001085193A2 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
EP2311867A1 (en) * 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc TREATMENT OF NEUROLOGICAL DISORDERS
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
EA018255B1 (ru) 2005-05-27 2013-06-28 Байоджен Айдек Ма Инк. Белки, связывающие tweak, и их применение
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｔｗｅａｋ及びヒトｉｌ１７に対する二重特異性抗体並びにその使用
JP2019535249A (ja) * 2016-10-24 2019-12-12 バイオイズ カンパニー リミテッド ＴＮＦ−α結合アプタマー及びその治療的用途
US11447778B2 (en) * 2018-04-20 2022-09-20 Academia Sinica TNF-targeting aptamers and uses thereof for treatment or diagnosing TNF-related inflammatory diseases
JP2024516548A (ja) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0531080A3 (en) 1991-09-04 1993-12-29 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein

Also Published As

Publication number Publication date
HUP9903921A2 (hu) 2000-03-28
JP2009183294A (ja) 2009-08-20
EP1591530B1 (en) 2015-02-25
CN101024831A (zh) 2007-08-29
EA003187B1 (ru) 2003-02-27
IS4967A (is) 1999-02-05
IL128407A (en) 2007-07-24
TR199900903T2 (xx) 1999-06-21
EP1591530A3 (en) 2009-04-08
JP4411330B2 (ja) 2010-02-10
DE69734397D1 (de) 2006-03-02
ES2251737T3 (es) 2006-05-01
IL128407A0 (en) 2000-01-31
EP1591530B8 (en) 2015-04-22
NO990550D0 (no) 1999-02-05
JP2007204480A (ja) 2007-08-16
KR100543730B1 (ko) 2006-01-23
JP2001505407A (ja) 2001-04-24
EP0956351A1 (en) 1999-11-17
NO990550L (no) 1999-04-06
NZ334107A (en) 2000-06-23
EP1591530A2 (en) 2005-11-02
DK0956351T3 (da) 2006-02-20
CN1232503A (zh) 1999-10-20
AU736289B2 (en) 2001-07-26
AU3829497A (en) 1998-02-25
NO20084906L (no) 1999-04-06
CZ297387B6 (cs) 2006-11-15
HK1025994A1 (en) 2000-12-01
PL188102B1 (pl) 2004-12-31
SK288012B6 (sk) 2012-10-02
WO1998005783A1 (en) 1998-02-12
HU226787B1 (en) 2009-10-28
ATE307204T1 (de) 2005-11-15
CA2262756A1 (en) 1998-02-12
DE69734397T2 (de) 2006-07-06
CZ40399A3 (cs) 1999-08-11
CA2262756C (en) 2012-06-12
CN1308451C (zh) 2007-04-04
BG64779B1 (bg) 2006-03-31
EP0956351B1 (en) 2005-10-19
EE9900043A (et) 1999-08-16
JP4161084B2 (ja) 2008-10-08
SI0956351T1 (sl) 2006-02-28
BG103169A (en) 2000-06-30
SK15799A3 (en) 2000-03-13
HUP9903921A3 (en) 2000-08-28
BR9711046A (pt) 2000-01-11
PL331583A1 (en) 1999-07-19
EA199900187A1 (ru) 1999-08-26
IS2606B (is) 2010-04-15
NO326967B1 (no) 2009-03-23
KR20000029877A (ko) 2000-05-25

Similar Documents

Publication Publication Date Title
EE05276B1 (et) Kasvaja nekroosifaktori sugulasligand
WO1999012965A3 (en) April- a novel protein with growth effects
EA200000311A1 (ru) Новый белок иммунной системы - кау
FI941459A (fi) Tuumorinekroositekijän muteiineja
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
FI901102A0 (fi) Farmaceutiska kompositioner.
FI922364A0 (fi) Farmaceutiska kompositioner.
DE68914483D1 (de) Harzzusammensetzungen und diese verwendende Mehrschichtstrukturen.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
DE69115263D1 (de) Pharmazeutische zusammensetzungen.
IT8920486A0 (it) Composizioni farmaceutiche.
FR2701264B1 (fr) Muteines de facteur de necrose tumorale.
DE69706146D1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
FR2673121B1 (fr) Melangeur.
FI920845A0 (fi) Farmaceutiska kompositioner innehaollande interleukin-2.
DE59005057D1 (de) Mischgaspumpen-Antrieb.
ITTO960379A0 (it) Composizione farmaceutica per malattie cardiovascolari e renali.
ITRM920415A1 (it) Composizione per uso chirurgico e sua applicazine per irrigazioni chirurgiche.
TR199500776A2 (tr) Farmasötik bilesimler.
IT233618Y1 (it) miscelatore di tipo perfezionato.
FI913070A0 (fi) Foerfarande och anordning foer stapling av tanerskivor.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
FI893437A (fi) Foerfarande foer stapling och avstapling av arkformiga foeremaol.

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231